Insulin analogues: a critical view on their future

Area of Science:

• Endocrinology
• Pharmacology
• Clinical Research

Background:

• Insulin analogues offer enhanced pharmacokinetic and pharmacodynamic profiles for diabetes management.
• Recent years have seen the market introduction of rapid-acting and long-acting insulin analogues.
• These formulations aim to optimize metabolic control in individuals with diabetes.

Purpose of the Study:

• To address the limitations in high-quality randomized controlled trials (RCTs) for insulin analogues.
• To discuss the challenges in evidence-based medicine regarding insulin analogue efficacy.
• To explore alternative endpoints beyond traditional metrics for evaluating insulin analogue benefits.

Main Methods:

• Review of existing literature on insulin analogue clinical trials.
• Analysis of evidence-based medicine criteria and their applicability.
• Discussion on the relevance of various study endpoints, including clinical and patient-reported outcomes.

Main Results:

• A scarcity of robust randomized controlled trials (RCTs) meeting stringent evidence-based medicine criteria exists for insulin analogues.
• Reimbursement for insulin analogues is becoming problematic in some European countries due to insufficient evidence.
• Current trial endpoints may not fully capture the clinically relevant benefits for patients, such as long-term morbidity/mortality or glucose variability.

Conclusions:

• There is a critical need for new clinical studies on insulin analogues, employing a fresh perspective.
• Relying on repeated discussions of old data is insufficient for evaluating new therapeutic developments.
• Future research should focus on endpoints more meaningful to patients, such as long-term health outcomes and glucose variability.